Please assess the completion status of the following clinical trial:

Trial Title: Rifaximin and Norfloxacin for Prevention of SBP in Adults With Decompensated Cirrhosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Low Ascitic fluid protein level \<1gm/dl~2. Advanced liver disease as evidenced by CTP≥9~3. Serum billirubin≥3 mg/dl~4. Impaired renal function defined by serum creatinine≥1.2 mg/dl~5. Blood urea nitrogen 25mg/dl~6. Serum sodium level≤ 1.2 meq/l~Exclusion Criteria:~1. Inability to obtain informed consent from patient or relatives.~2. Acute on chronic liver failure~3. Severe cardiopulmonary disease~4. Pregnancy~5. Age \<18yrs~6. Post liver transplant patients~7. HIV infection~8. Recent abdominal surgery(with in last 6 months)~9. Portal vein thrombosis~10. Splenectomy~11. Patient on immunosuppressive drugs except for alcoholic steatohepatitis~12. Patients on psychoactive drugs, such as antidepressants or sedatives~13. Hypersensitivity to norfloxacin and rifaximin~14. Malignancies including Hepatocellular carcinoma~15. Prior history of hepatic encephalopathy on Rifaximin -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Primary prophylaxis arm (Type: OTHER): 28 Patients with decompensated cirrhosis without past history of SBP were randomised to receive Rifaximin at dose 550 mg twice daily.29 Patients with decompensated cirrhosis without past history of SBP were randomized to receive Norfloxacin at dose 400 mg once daily
- Secondary prophylaxis arm (Type: OTHER): 26 Patients with decompensated cirrhosis with past history of SBP were randomized to receive Rifaximin at dose 550 mg twice daily.33 Patients with decompensated cirrhosis with past history of SBP were randomized to receive Norfloxacin at dose 400 mg once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).